Drug combination for the treatment of pain is common clinical practice. Co-crystal of Tramadol-Celecoxib (CTC) consists of two active pharmaceutical ingredients (APIs), namely the atypical opioid tramadol and the preferential cyclooxygenase-2 inhibitor celecoxib, at a 1:1 molecular ratio. In this study, a non-formulated 'raw' form of CTC administered in suspension (referred to as ctc susp ) was compared with both tramadol and celecoxib alone in a rat plantar incision postoperative pain model. For comparison, the strong opioids morphine and oxycodone, and a tramadol plus acetaminophen combination at a molecular ratio of 1:17 were also tested. Isobolographic analyses showed that ctc susp exerted synergistic mechanical antiallodynic (experimental ED 50 = 2.0 ± 0.5 mg/kg, i.p.; theoretical ED 50 = 3.8 ± 0.4 mg/kg, i.p.) and thermal (experimental ED 50 = 2.3 ± 0.5 mg/kg, i.p.; theoretical ED 50 = 9.8 ± 0.8 mg/kg, i.p.) antihyperalgesic effects in the postoperative pain model. In contrast, the tramadol and acetaminophen combination showed antagonistic effects on both mechanical allodynia and thermal hyperalgesia. No synergies between tramadol and celecoxib on locomotor activity, motor coordination, ulceration potential and gastrointestinal transit were observed after the administration of ctc susp . Overall, rat efficacy and safety data revealed that ctc susp provided synergistic analgesic effects compared with each API alone, without enhancing adverse effects. Moreover, ctc susp showed similar efficacy but improved safety ratio (80, measured as gastrointestinal transit vs postoperative pain ED 50 ratios) compared with the strong opioids morphine (2.5) and oxycodone (5.8). The overall in vivo profile of ctc susp supports the further investigation of CTC in the clinical management of moderate-to-severe acute pain as an alternative to strong opioids.
Introduction
Acute pain as a result of trauma, illness, or surgery is the most common symptom for which patients seek medical attention and the most common reason for admission to the emergency department (Sinatra, 2010) . Despite its high prevalence there are significant unmet needs in the management of acute pain. According to the Pain and Emergency Medicine Initiative study, 74% of patients admitted to emergency units were discharged in moderate-to-severe pain (Todd et al., 2007) . In addition, currently available pain-reducing drugs are often associated with poor tolerability and can be inconvenient to use due to frequent dosing schedules (Turk et al., 2011) .
The use of drug combinations can address some of these unmet medical needs. Pain is a complex phenomenon that results from a sum of contributing factors. Thus, treatments that act on different pain-associated molecular mechanisms may be more advantageous compared with treatments focused on a single molecular target (Mao et al., 2011) . Combining pain-reducing drugs at an optimal ratio for synergic analgesic effects can also minimize side effects, as lower doses of the individual drugs can be used (Mehlisch, 2002; Raffa et al., 2010; Wei-wu et al., 1999) . Fixed-dose combinations consist of two or more individual active pharmaceutical ingredients (API) produced in a single dosage form. However, a number of problems have been encountered during the development of these combinations, including issues relating to stability, solubility, and chemical interactions between the individual APIs. API-API co-crystals constitute a novel strategy that can overcome some of the problems associated with traditional fixed-dose combinations (Thipparaboina et al., 2016) . API-API co-crystals can display different physical and chemical properties compared with their parent APIs, such as improved solubility and dissolution rates but, as they are not modified covalently, each individual API retains its biological activity (Blagden et al., 2007; Yadav et al., 2009) .
Co-Crystal of Tramadol-Celecoxib (CTC) is an API-API co-crystal that combines two APIs with different mechanisms of action, tramadol (rac-tramadol. HCl) and celecoxib, in a 1:1 molecular ratio. Physicochemical data confirmed improved properties compared with the single APIs (Almansa et al., 2017) . Celecoxib is a non-steroidal antiinflammatory drug (NSAID) acting via inhibition of cyclooxygenase-2 (COX-2) (McCormack, 2011) . Tramadol is a centrally acting weak μ-opioid receptor agonist and an inhibitor of the neuronal noradrenaline and serotonin reuptake (Grond and Sablotzki, 2004) , with relatively low potential for misuse, abuse, and dependency (Radbruch et al., 2013; Raffa, 2008) .
In this study, the efficacy of a non-formulated 'raw' form of CTC administered in suspension (referred to as ctc susp ) was examined in a rat postoperative pain model and compared with that of tramadol and celecoxib given separately, in order to assess possible synergistic antinociceptive interactions, using isobolographic analysis. Strong opioids (morphine and oxycodone) and a combination of tramadol plus acetaminophen at a molecular ratio of 1:17 were also evaluated for comparison. In addition, the safety of ctc susp and its individual APIs was assessed via a number of rat models and endpoints. Motor locomotion and coordination were assessed as general safety parameters, and gastrointestinal transit and ulceration potential were evaluated as representatives of opioid and NSAID adverse effects, respectively.
Materials and methods

Animals
Male Wistar Han rats weighing 150-250 g (6-8 weeks-old, sexually immature) (Harlan, Italy) were used. Only male rats were used because no sex differences in drug pharmacokinetics, efficacy and safety were observed in phase I clinical trials (Videla et al., 2017) and in the phase II clinical for CTC (Videla et al., 2016) . Rats were housed in groups of five, provided with food and water ad libitum and kept in controlled laboratory conditions with temperature maintained at 21 ± 1°C and 12-h light/dark cycles with light on at 07:00 h. Experiments were carried out in a sound-attenuated, air-regulated experimental room during the light cycle. All experimental procedures and animal husbandry were conducted according to ethical principles for the evaluation of pain in conscious animals (Zimmermann, 1983) and to ethical guidelines as set out in the European Communities Council Directive of 22nd September 2010 (2010/63/EU), the Decree 214/1997 of 30th July 1997 (Generalitat de Catalunya, Spain), the Royal Decree 53/2013 of 1st February 2013 (Spain), and were subject to CEEA-PCB (Institutional Care and Use Committee) approval. Studies are reported in accordance with the Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines for experiments involving animals (Kilkenny et al., 2010) . Animals were euthanized by carbon dioxide asphyxiation at the end of the final testing period. All effort was taken to minimize the number of animals used and their suffering.
Drugs
Rats were randomly assigned to each treatment group by an individual other than the operator (n = 8-10/group, unless specified). Drugs were administered at different doses and via different routes depending on the experiment: ctc susp (Esteve Química, Barcelona, Spain), 0.625-320 mg/kg; rac-tramadol hydrochloride (Sigma Chemicals Co., St. Louis, MO, USA), 2.5-141 mg/kg; celecoxib (Esteve Química, Barcelona, Spain), 0.6-179 mg/kg; acetaminophen (Alfa Aesar GmbH & Co KG, Karlsruhe, Germany), 40-320 mg/kg; naproxen sodium (Sigma-Aldrich, Tres Cantos, Madrid, Spain), 60 mg/kg; oxycodone hydrochloride (Johnson-Matthey, London, UK), 2.5-10 mg/ kg; morphine hydrochloride (General Directorate of Pharmacy and Drugs, Spanish Ministry of Health, Madrid, Spain), 0.625-10 mg/kg. Drug mixtures were prepared by Esteve (Barcelona, Spain) for this study, including the mixture of tramadol and acetaminophen at a molecular ratio (i.e., the ratio between the amounts in moles of the two compounds) of 1:17 (1:8.7 wt ratio). Compounds were dissolved or suspended in 0.5% hydroxypropylmethylcellulose (HPMC, SigmaAldrich, Tres Cantos, Madrid, Spain) in distilled water and administered in a volume of 10 ml/kg via the intraperitoneal (i.p.) or, in the case of the gastrointestinal ulceration study, oral (p.o.) route. In these conditions, ctc remains in suspension without dissociating in their components before co-crystal administration to the animals. All dose formulations were prepared fresh daily.
Measurement of antinociceptive activity
Postoperative pain model
Experiments were performed according to the procedure described by Brennan et al. (1996) . Briefly, animals were anesthetized using 3% isoflurane (IsoFlo ® , Abbott-Esteve, Barcelona, Spain). Once anesthetized, a 1 cm longitudinal incision was made through skin and fascia of the plantar aspect of the right hindpaw, using a number 23 scalpel, starting 0.5 cm from the proximal edge of the heel and extending toward the toes. Superficial (skin), deep (muscle) tissues, and nerves were injured. Finally, the incision was closed with a suturing stitch using braided silk (3.0) and the area cleaned with povidone-iodine (Betadine ® , Meda Pharma, Madrid, Spain). Behavioral tests (mechanical allodynia and thermal hyperalgesia) were performed four h after surgery (one h after vehicle or drug administration).
Mechanical allodynia
Mechanical allodynia was quantified, as previously described by Chaplan et al. (1994) , by determining the pressure threshold eliciting withdrawal of the ipsilateral and contralateral hind paws in response to stimulation with von Frey filaments applied to the plantar surface (the toes and heels were avoided). Rats were placed inside clear plastic boxes above a wire mesh floor, which allowed full access to the paws. Behavioral acclimatization was allowed for at least 15 min. Mechanical paw withdrawal thresholds were measured via the up-down testing paradigm (Chaplan et al., 1994; Dixon, 1980) , using von Frey filaments in log increments of force (0.4, 0.6, 1, 2, 4, 6, 10, and 15 g) . Filaments were applied to the test area for approximately three s each, with an interstimulus interval of approximately 1 min. The 2 g stimulus was applied first. Fifty per cent paw withdrawal threshold values were derived according to the method previously described by Chaplan et al. (1994) . Behavioral evaluation was performed 1 h after treatment with either vehicle or drug. One h was selected because it allows reaching enough plasma levels of both celecoxib and tramadol (including active metabolites) and it is consistent with the literature for both compounds. The percentage of allodynia was calculated with respect to the corresponding contralateral paw, i.e. (contralateral -ipsilateral/contralateral) × 100. Percentage of antiallodynic effect for each treatment was calculated with respect to a vehicle-treated group, i.e. (vehicle group -treatment group/vehicle group) × 100.
Thermal hyperalgesia
Hyperalgesia was assessed by measurement of response to a thermal stimulus using a Hargreaves apparatus (Ugo Basile plantar test) (Dirig et al., 1997; Hargreaves et al., 1988) . Animals were placed in methacrylate cages with a crystal floor. The acclimatization period within the cages was approximately 10 min. The thermal stimulus (85 mW/cm 2 )
was applied via a mobile lamp below the crystal floor, which was applied to both paws in turn, with a minimum interval of one min between stimulations, in order to avoid learning behaviors. The ipsilateral paw was tested first, followed by the contralateral paw. The thermal stimulus was terminated when the rat withdrew its paw (animals had free movement within the cages) or when the maximum threshold time of 32 s was reached (this elicited automatic cut-off of the thermal stimulus). Latency time to the withdrawal response was then recorded.
Behavioral evaluation was performed one h after treatment with either vehicle or drug. The percentage of hyperalgesia was calculated with respect to the corresponding contralateral paw, i.e. (contralateralipsilateral/contralateral) × 100. Percentage of antihyperalgesic effect for each treatment was calculated with respect to a vehicle-treated group, i.e. (vehicle group -treatment group/vehicle group) × 100.
Safety tests
All safety tests were performed in naïve, non-operated animals.
Motor coordination
The motor performance of rats was assessed by means of an automated rotarod (Panlab S.L., Spain). Briefly, rats were required to walk against the motion of an elevated rotating drum at 10 rpm and the latency to fall was recorded automatically. The day before vehicle or drug treatment, rats were trained (at least three sessions of 240 s each) and animals that were unable to stay moving on the rod for 240 s were excluded from the study (less than 5%). Rotarod latencies of selected animals were measured 30, 60, 120 and 180 min after the i.p. administration of vehicle or drug, with a cut-off of 240 s. The percentage of motor coordination impairment was calculated as the percent reduction in the area under the curve obtained from the endpoints at 30, 60, 120 and 180 min after drugs administration with respect to a vehicle-treated group, i.e. (vehicle group -treatment group/vehicle group) x 100.
Locomotor activity
Locomotor activity was measured using 45 × 22 × 30 cm standard actimeter cages (Linton Instrumentation Inc., UK) equipped with infrared beams for the detection of movement. After administering the vehicle or drug, animals were returned to their homecages and then placed in the locomotor activity cages 30 min later. The percentage of locomotor activity was calculated using the moving time measured for 30 min and collected every 5 min, with respect to a vehicle-treated group, i.e. (vehicle group -treatment group/vehicle group) × 100.
Gastrointestinal transit
Gastrointestinal transit was determined by identifying the leading front of an intragastrically administered marker (charcoal) in the small intestine of rats. Charcoal meal (5% in distilled water) was freshly prepared. Thirty min after i.p. administration of vehicle or drug, each rat received 0.5 ml of charcoal suspension intragastrically, using an oral cannula. After 30 min, animals were euthanized. Immediately after, the abdomen was opened and the entire length of small intestine was isolated by cutting at the pyloric and ileocecal ends. The distance traveled by the charcoal meal and the total length of the intestine were measured in centimeters. The intestinal transit was expressed as a percentage of the distance traveled by the charcoal to the length of the intestine.
Gastrointestinal ulceration
After 16 h of starvation, vehicle or drug was orally administered. Three h later, rats were euthanized, the stomach removed and the number of ulcers counted. The injured area was also measured in square millimeters, using the Micro Image Olympus ® software (version 4.0, Olympus Optical Co, Hamburg, Germany).
Data analysis 2.5.1. Isobolographic analysis
Isobolographic analysis represents the gold standard for the demonstration of pharmacological interactions between chemical compounds (Tallarida, 2001 ). This method was used to compare the effects of several doses (0.625-320 mg/kg, depending on the experiment) of ctc susp with the effects achieved using different doses of each of the two individual APIs. The median effective dose (ED 50 ) values of the drugs and combinations were determined from their dose-response curves using standard nonlinear regression analysis of log dose-response. To analyze the interaction between tramadol and celecoxib in each combination, isobolographic analysis was performed according to Tallarida (2001) . The additive isobole was obtained by connecting the ED 50 of celecoxib plotted on the abscissa with the ED 50 of tramadol on the ordinate. When drugs gave different maximum effects, the resulting isobole of additivity was hyperbolic (curvilinear) because individual dose-response curves reveal a non-constant potency ratio (Raffa et al., 2010) . Alternatively, when one of the drugs lacked efficacy the additive isobole was horizontal. The theoretical additive dose (Zadd) for a combination was calculated and compared with the experimental ED 50 (Zt) of the combination. The interaction between two drugs was classified using the interaction index (γ = Zt/Zadd): (1) supra-additive or synergistic interaction (γ < 1), with significant differences between Zt and Zadd; (2) sub-additive or antagonistic interaction (γ > 1), with significant differences between Zt and Zadd and (3) additive interaction (γ ≈ 1), without significant differences between Zt and Zadd.
Statistical analysis
Data are presented as percentages of antiallodynic and antihyperalgesic effect of treatments i.e. (vehicle -treatment/vehicle) × 100 ± standard error of the mean (S.E.M.). A one-way analysis of variance (ANOVA) followed by the Dunnett's multiple comparison test was used to test for differences among several groups. A non-paired Student's t-test was used to test for differences between two groups. The level of significance was set at P < 0.05. E max and ED 50 were calculated from the dose-response curves using nonlinear regression analysis. S.E.M. was calculated from the best-fit values of regression. Data analysis and graphics were done using GraphPad Prism software (version 4.0; GraphPad Software, Inc., USA).
Results
3.1. Mechanical antiallodynic and thermal antihyperalgesic effects of tramadol, celecoxib, and ctc susp after paw incision Dose-response curves of tramadol, celecoxib, and ctc susp were obtained to determine their efficacies and potencies on mechanical allodynia (Fig. 1A ) and thermal hyperalgesia (Fig. 1C) in the rat incisional paw model of postoperative pain. Morphine and oxycodone were also tested on mechanical allodynia. ED 50 ( ± S.E.M.) values for mechanical allodynia when stimulated on the right, ipsilateral hindpaw were 2.2 ± 0.1, 1.2 ± 0.1, 5.4 ± 0.8, 3.0 ± 0.5, and 2.0 ± 0.5 mg/kg i.p. for morphine, oxycodone, tramadol, celecoxib, and ctc susp , respectively. ED 50 ( ± S.E.M.) values for thermal hyperalgesia were 8.3 ± 1.2, 2.6 ± 1.5, and 2.3 ± 0.5 mg/kg i.p. for tramadol, celecoxib, and ctc susp , respectively. All compounds showed full efficacy in this model, except for celecoxib in thermal hyperalgesia (E max = 47%). Isobolographic analysis showed significant differences (P < 0.05) between the experimental ED 50 Zt (2.0 ± 0.5 mg/kg, i.p.) and the theoretical Zadd (3.8 ± 0.4 mg/kg, i.p.), with an interaction index γ = 0.5 (γ = Zt/Zadd), indicating a synergistic/supra-additive effect of tramadol and celecoxib when administered as ctc susp on mechanical allodynia (Fig. 1B) . Similarly, significant differences were found (P < 0.001) between the experimental ED 50 Zt (2.3 ± 0.5 mg/kg, i.p.) and the theoretical Zadd (9.8 ± 0.8 mg/kg, i.p.), with an interaction index γ = 0.2, indicating a synergistic/supra-additive effect of tramadol and celecoxib when administered as ctc susp on thermal hyperalgesia (Fig. 1D) .
Mechanical antiallodynic and thermal antihyperalgesic effects of tramadol, acetaminophen, and their combination after paw incision
In a separate group of experiments, dose-response curves of tramadol, acetaminophen, and the combination of tramadol and acetaminophen at a molecular ratio 1:17 (weight ratio 1:8.7) were obtained to determine their efficacies and potencies on mechanical allodynia ( Fig. 2A ) and thermal hyperalgesia (Fig. 2C) in the incisional paw model of postoperative pain. Tramadol plus acetaminophen fixed-dose combination is already available in clinical practice (tramadol 37.5 mg; acetaminophen 325 mg), thus the ratio used in the present study was selected on the basis of the proportion of both drugs in the current clinically available combination (Dhillon, 2010) . ED 50 ( ± S.E.M.) values for mechanical allodynia when stimulated on the right, ipsilateral hindpaw were 4.0 ± 0.4, 112.4 ± 10.0, and 39.5 ± 4.1 mg/kg i.p. for tramadol, acetaminophen, and their 1:17 combination. ED 50 ( ± S.E.M.) values for thermal hyperalgesia were 3.3 ± 0.5, 87.2 ± 6.1, and 75.0 ± 5.9 mg/kg i.p. for tramadol, acetaminophen, and their 1:17 combination. All compounds showed full efficacy in this model. An antagonistic/sub-additive effect of tramadol and acetaminophen on mechanical allodynia and thermal hyperalgesia was observed for the combination after isobolographic analysis, with significant differences between the experimental ED 50 Zt (39.5 ± 4.1 and 75.0 ± 5.9 mg/kg i.p. for mechanical allodynia and thermal hyperalgesia, respectively) and the theoretical Zadd (27.6 ± 2.2 and 24.2 ± 1.6, respectively) with an interaction index γ = 1.4 and 3.1, respectively (Fig. 2B, D) .
Effects of tramadol, celecoxib, and ctc susp on motor locomotion and coordination
Dose-response curves of tramadol, celecoxib, and ctc susp were obtained to determine their effects on motor locomotion and coordination using the locomotor activity and rotarod tests respectively. ED 50 ( ± S.E.M.) values for motor activity impairment were 35.1 ± 1.0, and 87.6 ± 1.9 mg/kg i.p. for tramadol, and ctc susp , respectively, whereas ED 50 ( ± S.E.M.) values for motor coordination impairment were 74.5 ± 1.1, and 160.1 ± 1.9 mg/kg i.p. for tramadol, and ctc susp respectively. Celecoxib did not show a significant effect at doses up to 160 mg/kg, i.p. (Fig. 3A, C) . When ctc susp was administered, isobolographic analysis showed an additive effect of tramadol and celecoxib on the locomotor activity test and rotarod test with no significant difference between the experimental ED 50 Zt (87.6 ± 1.9 and 160.1 ± 1.9 mg/kg, i.p. for locomotor activity and rotarod test, respectively) and the theoretical Zadd (81.5 ± 1.9 and 165.3 ± 13.3 mg/kg, i.p.), with an interaction index of γ = 1.1 and 1.0, respectively (Fig. 3B, D) .
Effects of morphine, oxycodone, tramadol, celecoxib, and ctc susp on gastrointestinal transit
Dose-response curves of morphine, oxycodone, tramadol, celecoxib, and ctc susp were obtained to determine their effects on gastrointestinal transit, a common opioid-induced adverse effect. Celecoxib did not show a significant effect at doses up to 160 mg/kg i.p., whereas all opioids showed dose-dependent reductions in gastrointestinal transit (Fig. 4A-C) . When ctc susp was administered a maximum reduction of 48% in gastrointestinal transit was obtained at the highest dose tested, Fig. 1 . Dose-response effects of morphine, oxycodone, tramadol, celecoxib, and ctc susp in a rat postoperative pain model. The percentages of mechanical antiallodynic (A) and thermal antihyperalgesic (C) effect were measured one h after i.p. drug administration. Isobolographic analysis indicated a synergistic/supraadditive effect on mechanical allodynia (B) and thermal hyperalgesia (D) of tramadol and celecoxib when ctc susp was administered. *P < 0.05, ***P < 0.001 significant difference between Zadd and Zt (Student's t-test). Data are percentages ± S.E.M. ctc susp , co-crystal of Tramadol -Celecoxib in a molecular ratio of 1:1 in suspension; ED 50 , median effective dose; i.p., intraperitoneal; Zadd, theoretical ED 50 ; Zt, experimental ED 50 .
i.e. 160 mg/kg i.p. (Fig. 4D) . Efficacy (mechanical allodynia) values obtained in the postoperative pain model are included in the figures to better appreciate the therapeutic windows of each drug. ED 50 ratios for efficacy and reduction of gastrointestinal transit were 2.5, 5.8, 10.3, and approximately 80 for morphine, oxycodone, tramadol, and ctc susp , respectively. Thus, ctc susp showed the best safety ratio when comparing efficacy data in the postoperative pain model and opioid-induced adverse effects measured as a reduction in gastrointestinal transit.
Ulcerogenic activity of tramadol, celecoxib, and ctc susp
The effects of tramadol, celecoxib and ctc susp on stomach integrity as measured by the number of ulcers and area of injury are summarized in Table 1 . Doses of celecoxib and tramadol were those corresponding in weight to the equimolar proportion 1:1 in 320 mg/kg ctc susp . Neither tramadol (141 mg/kg p.o.) nor ctc susp (320 mg/kg p.o.) induced gastric ulcers. Celecoxib (179 mg/kg p.o.) was almost inactive, with only one animal having a small ulcer of 0.24 mm 2 . Conversely, the NSAID naproxen (60 mg/kg p.o.), used as a positive control, induced a statistically significant increase in the number of ulcers compared with vehicle-treated rats (P < 0.01), with a total injured area of 6.3 ± 1.4 mm 2 .
Discussion
The ultimate goal of a drug combination is to increase the therapeutic effect but not the adverse effects; that is, to have a better benefit-risk ratio compared with the individual APIs. Thus, the main objectives of these studies were to examine the antinociceptive efficacy of the co-crystal ctc susp , which is a combination of tramadol and celecoxib in a 1:1 molecular ratio (Almansa et al., 2017) , in a preclinical model of postoperative pain, and to quantitatively evaluate the interaction between tramadol and celecoxib in terms of antinociception and safety.
Determining whether a particular drug combination has synergistic activity requires rigorous quantitative analysis in animal models followed by adequate clinical assessment (Raffa et al., 2010; Tallarida, 2001) . Isobolographic analysis represents the gold standard for the demonstration of pharmacological interactions and has been used in animal models of pain to demonstrate the supra-additive effects of clinically available drug combinations (Maves et al., 1994; Ortiz et al., 2007; Tallarida and Raffa, 1996) .
An optimal strategy for pain management is to combine drugs that contribute through multiple mechanisms to the therapeutic endpoint. CTC can potentially recruit at least four different mechanisms. Celecoxib is an NSAID that primarily acts via inhibition of COX-2 (McCormack, 2011) . Tramadol is a centrally acting weak synthetic μ-opioid receptor agonist and an inhibitor of the neuronal reuptake of noradrenaline and serotonin. In fact, tramadol is a racemic compound with two enantiomers: the (+)-enantiomer has higher affinity for μ-opioid receptors and is a more potent inhibitor of serotonin reuptake, whereas the (-)-enantiomer is a more potent inhibitor of noradrenaline reuptake. Additionally, the O-desmethyl metabolite of tramadol, which has a higher affinity for the μ-opioid receptors than the parent compound, also contributes to its analgesic effects (Grond and Sablotzki, 2004) . All of these mechanisms are relevant in pain circuitry, involving both ascending and descending pathways, as well as peripheral (COX-2) and central (mu opioid) areas involved in pain processing. Thus, CTC, acting at several levels, could attain more efficient pain control than strategies acting through a single mechanism. Fig. 2 . Dose-response effects of tramadol, acetaminophen and their combination in a rat postoperative pain model. The percentages of mechanical antiallodynic (A) and thermal antihyperalgesic (C) effect were measured one h after i.p. administration of tramadol, acetaminophen or their combination at the molecular ratio 1:17 (weight ratio: 1:8.7). Isobolographic analysis indicated an antagonistic/sub-additive effect on mechanical allodynia and thermal hyperalgesia of tramadol and acetaminophen when the combination was administered (B, D). *P < 0.05, ***P < 0.001 significant difference between Zadd and Zt (Student's t-test). Data are percentages ± S.E.M. ED 50 , median effective dose; i.p., intraperitoneal; Zadd, theoretical ED 50 ; Zt, experimental ED 50 .
NSAIDs and opioids are the most commonly used analgesics in the management of acute and chronic pain. Although clinical studies with NSAIDs and opioids suggest an additive or possibly synergistic interaction, few quantitative studies aiming to reveal the nature of the interaction have been conducted (Picard et al., 1997; Wei-wu et al., 1999; Wideman et al., 1999) . Quantifying an antinociceptive synergistic effect presents practical and ethical limitations in human subjects. Thus, the use of adequate animal models of nociception is a useful tool to explore such combinations. For example, in a rat model of visceral pain caused by colonic distension, ketorolac showed no activity alone but potentiated morphine antinociception (Maves et al., 1994) . Similarly, metamizol potentiated morphine effects in a model of acetic acid-induced visceral pain (Taylor et al., 1998) , and low doses of acetylsalicylic acid were able to potentiate morphine effects in hot-plate and formalin tests in rats (Sandrini et al., 1998) . López-Muñoz and coworkers have described several positive interactions between opioids, such as morphine, D-propoxyphene and tramadol, and NSAIDs including acetylsalicylic acid, acetaminophen, ketorolac, or metamizol in rat pain models (Déciga-Campos et al., 2003; López-Muñoz, 1994; López-Muñoz et al., 1993 , 1994 , 2008 Moreno-Rocha et al., 2012; Salazar et al., 1995) . Nevertheless, the co-administration of opioids and NSAIDs does not always result in synergy or additivity, as sub-additive results have also been described (García-Hernández et al., 2007) .
Combinations of opioids and NSAIDs are commonly used to control postoperative pain in clinical practice (Buvanendran and Kroin, 2009; Picard et al., 1997; Wideman et al., 1999) . Postoperative pain is a common form of acute pain, and one in which both central and peripheral sensitization play an important role. In the present study, systemic administration of ctc susp resulted in a synergistic analgesic interaction between tramadol and celecoxib to inhibit pain-related behaviors. In fact, the analgesic potency of ctc susp was several times greater than those of the individual APIs when compared on a molar basis (6-7 times with respect to tramadol and 1.8-2.6 times with respect to celecoxib). These results suggest a synergy among the four molecular mechanisms present in ctc susp described above. It has been suggested that COX inhibitors may potentiate opioid inhibitory action on GABA interneurons, which form part of the descending antinociceptive pathways (López-Muñoz et al., 2004; Vaughan, 1998) . Also, the potentiation of morphine effects by acetylsalicylic acid and acetaminophen is associated with an increase in serotonin levels in rat cortex (Sandrini et al., 1998 (Sandrini et al., , 1999 . Thus, potentiation of serotoninergic pathways could contribute to the synergy observed with ctc susp , more so considering the additional inhibitory effect of tramadol on serotonin reuptake. However, the impact of other pharmacodynamic/pharmacokinetic interactions on synergy cannot be excluded. In fact, pharmacokinetic properties of tramadol and celecoxib when administered as the co-crystal are modified in comparison with those of the single components (Videla et al., 2017) . In accordance with our preclinical findings, preoperative rofecoxib administration improved analgesia and reduced tramadol consumption in patients undergoing abdominal hysterectomy (Karamanhoğlu et al., 2004) . Also, preoperative use of celecoxib, rofecoxib or diclofenac decreased pain intensity and reduced tramadol requirements in laparoscopic Nissen fundoplication surgery (Alanoglu et al., 2005) .
A consistent finding that has emerged from combination studies is that drug synergism is not simply dependent on the intrinsic properties of the individual APIs but also depends on their proportion in the combination (López-Muñoz et al., 2004; Salazar et al., 1995; Tallarida and Raffa, 1996) . In the case of CTC, the proportion of tramadol and Fig. 3 . Dose-response inhibition of rat locomotion and motor coordination (rotarod test) by tramadol, celecoxib and ctc susp . Locomotor activity (A) and rotarod test (C) were performed after i.p. administration of tramadol, celecoxib or ctc susp . Isobolographic analysis of the locomotor activity data (B) and rotarod data (D) showed no statistically significant interaction between tramadol and celecoxib following administration of ctc susp (Student's t-test). Data are percentages ± S.E.M. ctc susp , cocrystal of Tramadol -Celecoxib in a molecular ratio of 1:1 in suspension; i.p., intraperitoneal; n.s., not statistically significant. celecoxib present in the co-crystal (1:1 molecular ratio; 1:1.27 wt ratio) produced increased analgesic synergism with reduced side effects. This ratio is consistent with the clinically approved daily doses of tramadol and celecoxib. On the contrary, the commercially available combination of tramadol and acetaminophen (tramadol 37.5 mg; acetaminophen 325 mg; i.e. 1:17 molecular ratio or 1:8.7 wt ratio) showed sub-additive effects for both mechanical allodynia and thermal hyperalgesia behaviors. Tallarida and Raffa (1996) showed that only some tramadol acetaminophen weight ratios, including and above 1:19, provided synergistic analgesia in the writhing test in mice.
Additionally, the nature of read-outs could also affect the evaluation of the interaction. To our knowledge, preclinical data in a rat postoperative pain model have not been reported for a tramadol acetaminophen combination. Clinical studies have demonstrated the efficacy of tramadol acetaminophen combination in acute postoperative dental pain (Edwards et al., 2002; Fricke et al., 2002 Fricke et al., , 2004 , postoperative pain following orthopedic or abdominal surgery (Bourne et al., 2005; Smith et al., 2004) and hand surgery (Rawal et al., 2011) . The fact that the combination of tramadol and acetaminophen is efficient in clinical trials, even more than the components alone does not inform about the nature of the pharmacodynamic interaction. A conclusion of a synergistic, additive or antagonistic behavior of a drug combination can be drawn only after an isobolographic analysis, which is indeed very difficult in a clinical context. In fact, a combination of two drugs could be antagonistic in nature, which indicates that the effects are lower than those expected from the sum of the activities of both components, and still have more activity than each component alone.
No significant interaction of tramadol and celecoxib was observed when administered as ctc susp in terms of locomotor activity or motor coordination. The observed effects may be solely attributed to tramadol since celecoxib did not have any effect when administered alone at the tested doses. Tramadol at high doses is known to reduce motor activity in rats (Loram et al., 2007) . NSAIDs are known to increase the risk of gastrointestinal side effects (Hollenz et al., 2006) . The selective COX-2 inhibitor celecoxib has been reported to produce fewer upper gastrointestinal adverse effects than non-selective inhibitors (McCormack, 2011) . On the other hand, the participation of the opioid receptor in Doses of celecoxib and tramadol were those corresponding in weight to the equimolar proportion 1:1 in 320 mg/kg ctc susp . Data are mean ± S.E.M. Number of ulcers and injured area were measured 3 h after vehicle or drug administration. a P < 0.01 versus 0.5% HPMC group (one-way analysis of variance, followed by Dunnett's test). ctc susp , co-crystal of Tramadol -Celecoxib in a molecular ratio of 1:1 in suspension; HPMC, hydroxypropylmethylcellulose; p.o., oral administration.
gastroprotection has been described (Esplugues et al., 1992) . In our experimental conditions, neither tramadol nor celecoxib alone had ulcerogenic effects. ctc susp at a dose of 320 mg/kg, much higher than doses showing analgesic efficacy, did not induce gastric lesions after acute treatment. Our results are in accordance with others showing that tramadol did not potentiate gastric injury induced by ketorolac in rats (López-Muñoz et al., 2004) . Constipation is the most prevalent patient complaint associated with opioid use, affecting an estimated 40% of patients with nonmalignant pain and 70-95% of patients with cancer pain (DePriest and Miller, 2014) , and is associated with reductions in several quality of life measures (Coyne et al., 2014) . In our study, the strong opioids morphine and oxycodone showed no clear dissociation between efficacy in the postoperative pain model and effects on gastrointestinal transit. Tramadol demonstrated a slightly better therapeutic window, possibly due to the contribution of serotonin and noradrenaline reuptake inhibition to its analgesic activity. Contrary to the opioids tested, ctc susp clearly dissociated both effects, exhibiting high antinociceptive efficacy at doses showing little effect on gastrointestinal transit. Thus, CTC may provide a useful clinical therapeutic alternative to opioids, by maintaining efficacy and reducing opioidrelated adverse effects, including constipation. This study has demonstrated that ctc susp (nonformulated 'raw' CTC, administered in suspension) offers improved therapeutic effects and a better benefit-risk ratio, relative to those of its individual APIs, in a rat postoperative pain model. Moreover, ctc susp compared favorably with the strong opioids morphine and oxycodone in rat models, as it provided full efficacy with fewer opioid-induced adverse effects. A 4-week repeated-dose oral toxicity study in rats, assessing the toxicological profile of the co-crystal compared to its individual active components (at equivalent doses) concluded that the co-crystal administration does not modify the toxicological profile of the individual active compounds tramadol and celecoxib and has no additive or potentiating adverse effects. CTC has completed phase I clinical studies which have demonstrated similar or improved safety, tolerability and pharmacokinetic profiles in humans compared with effective doses of tramadol and celecoxib alone (Videla et al., 2017 (Videla et al., , 2018 . In addition, efficacy has been reported in a double-blind, placebo-controlled, phase II clinical study in the postoperative management of moderate-to-severe pain following extraction of two or more impacted third molars requiring bone removal (Videla et al., 2016) . CTC (100-200 mg, equivalent to 44-88 mg tramadol and 56-112 mg celecoxib) provided greater efficacy over tramadol 100 mg and placebo. Pain relief was associated with similar (200 mg dose) or better (100-150 mg doses) overall safety and tolerability than tramadol 100 mg alone. These clinical results support the further investigation of CTC in the clinical management of moderate-to-severe acute pain as an alternative to strong opioids.
